

Registered number: 701131
Charity number: CHY 14542
Charities Regulatory Authority Number 20047726

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

OESOPHAGEAL CANCER FUND

CONTENTS

	Page
Reference and administrative details of the Charity, its Directors and advisers	1
Chairman's statement	2
Directors' report	3 - 9
Statement of financial activities	10
Balance sheet	11
Statement of cash flows	12
Notes to the financial statements	13 - 22

OESOPHAGEAL CANCER FUND

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS DIRECTORS AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2022

Directors	Martin MacDonnell David Ryan Paul Paterson Sampada Lumba Marc Johnstone (appointed 13 January 2022) Sean Broderick (appointed 13 December 2022) Julie Colby (resigned 20 April 2022) David Curtis (appointed 13 December 2022) Noelle Ryan (appointed 13 December 2022)
Company registered number	701131
Charity registered number	CHY 14542 Charities Regulatory Authority Number 20047726
Registered office	16 Merville Road Stillorgan Dublin
Company secretary	Sampada Lumba
Chief executive officer	Christine Littlefield
Independent auditors	Woods and Partners Limited Chartered Accountants and Registered Auditor The Taney Buildings 3 Eglinton Terrace Dundrum Dublin 14
Bankers	Bank of Ireland New Century House IFSC Mayor Street Dublin 1
Solicitors	Hayes Solicitors Lavery House Earlsfort Terrace Dublin 2

OESOPHAGEAL CANCER FUND

CHAIRMAN'S STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2022

The chairman presents his statement for the year.

2022 marks 21 years in operation for the Oesophageal Cancer Fund (OCF). The charity was founded on a challenge from Lucilla Hyland a young woman diagnosed with Oesophageal Cancer in 2001 who sadly lost her hard-fought battle. Lucilla wanted there to be better awareness of Oesophageal Cancer to deliver early diagnosis and successful treatments. Lucilla envisioned that everyone affected by Oesophageal Cancer receives the earliest and best support and treatment possible. Lucilla Hyland laid down a challenge and we continue to be unwavering in our determination to deliver.

In 2022 the new strategic plan for the charity was launched. This plan will guide the work and development of the charity until the end of 2026. Over the course of this plan 2022 - 2026 we want to build on the work achieved so far for the organisation.

We defined clear objectives in the strategic plan, continuing to commit ourselves to raise awareness and advance knowledge of Oesophageal Cancer and Barrett's Oesophagus. Provide support and information and reflect the experiences and need of people affected by Oesophageal Cancer and Barrett's Oesophagus. Raise funds for research into Oesophageal Cancer to increase prevention and early diagnosis of Oesophageal Cancer and enhance survivorship.

We began 2022 with a new Board of Trustees all of whom have had family or friends touched by cancer in some form mainly Oesophageal Cancer. The Board comes from a wide range of backgrounds. I want to thank the Board for their time, skills and professionalism. Under their leadership, the Oesophageal Cancer Fund continues to focus on the difficulties and challenges that Oesophageal Cancer presents whilst meeting the highest governance and financial standards. Their detailed oversight and support has contributed hugely to the development of the organisation in 2022. In addition, I would like to commend the staff team for their contribution to the development and delivery of the new strategy in 2022.

I would like to thank our donors, supporters and partners and our Patron Pdraig Harrington, for the continued support of the organisation in 2022. I would also like to thank the people who have been affected by Oesophageal Cancer for their input, insight and ongoing support. They inspire us every day by their enormous determination to overcome and to give back and help others affected by Oesophageal Cancer.



Chairman

Date: 26 - 9 - 2023

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

The Directors present their annual report together with the audited financial statements of the Oesophageal Cancer Fund for the year 1 January 2022 to 31 December 2022. The Annual report serves the purposes of both a Trustee' report and a directors' report under company law. The Trustee confirm that the Annual report and financial statements of the charity comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in Republic of Ireland (FRS102).

Objectives and activities

a. The history of the Charity

The charity was founded in 2001 by a group of friends when one of their closest friends Lucilla Hyland lost her battle to Oesophageal Cancer. Lucilla's closest friends founded the charity in her honour to help others with this difficult cancer. They began with a dinner dance fundraiser, and soon turned their attention to the idea of Lollipop Day as a way of raising funds for Oesophageal Cancer research and awareness of the symptoms of Oesophageal Cancer.

The founding trustees and the CEO since inception, Noelle Ryan, gave an enormous amount to the organisation and the community of people with Oesophageal Cancer and survivors of Oesophageal Cancer. Noelle Ryan stepped aside in 2021 and handed over her role to Christine Littlefield. Two of the founding Trustees stepped aside in 2021 and the third in 2022 to the new Board of the Oesophageal Cancer Fund. The charity owes a huge debt of gratitude to Noelle Ryan and the founding trustees for their commitment, leadership and expertise.

b. Key organisational activities

The Oesophageal Cancer Fund is the national charity for Oesophageal Cancer in Ireland.

- Raising awareness and advancing knowledge of Oesophageal Cancer and Barrett's Oesophagus.
- Providing support and information and reflecting the experiences and need of people affected by Oesophageal Cancer and Barrett's Oesophagus.
- Raising funds for research into Oesophageal Cancer to increase prevention and early diagnosis of Oesophageal Cancer and enhance survivorship.

The Oesophageal Cancer Fund's Organisational Impact

We want to ensure that we work in the best interests of those affected by Oesophageal Cancer and Barrett's Oesophagus and we are determined to make progress within our areas of strategic priority and deliver positive impact for people affected by Oesophageal Cancer their families and carers.

The organisational impact we want to make working with our partners is to;

- Truly support and reflect the patient experience of Barrett's Oesophagus and Oesophageal Cancer in Ireland
- Raise awareness of Oesophageal Cancer in the public mind
- Reduce the incidence of Oesophageal Cancer focusing on Oesophageal Cancer prevention
- Enhance survivorship by increasing early diagnosis of Oesophageal Cancer
- Ensure holistic support for everyone affected Barrett's Oesophagus and Oesophageal Cancer
- Advance knowledge of Barrett's Oesophagus and Oesophageal Cancer that will deliver early diagnosis and tailored and successful treatments

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Objectives and activities (continued)

c. Vision, mission and values

In 2022 The organisational Vision, Mission and Values were redefined, while the vision and direction has changed for the charity with the new Strategic Plan, we have not lost sight of our values, these were formed when starting the charity, and are mirrored now, by the personal values of Lucilla Hyland.

Vision

The Oesophageal Cancer Fund is the national charity for Oesophageal Cancer in Ireland. Bringing the good fight to a difficult cancer.

The Vision of the Oesophageal Cancer Fund (OCF) is that everyone affected by Oesophageal Cancer receives the earliest and best support and treatment possible. We are committed to creating better awareness of Oesophageal Cancer - the risks and symptoms - to deliver early diagnosis and successful treatments.

Mission

The Mission of the Oesophageal Cancer Fund is to foster a culture of partnership. Working with people affected by Oesophageal Cancer their families, clinicians, researchers, volunteers and other support and advocacy organisations. Together we want to improve the experiences and outcomes of people with Oesophageal Cancer through our dedicated support, advancing knowledge and awareness and engaging in research.

Values

The Oesophageal Cancer Fund's core values are inspired by Lucilla Hyland, how she was as a person and they are expressed in all that we do.

Our Values;

- We are Courageous – We stand up for what is right and face challenges with determination to get things done.
- We are Collaborative – We thrive when working together.
- We Empower - We recognise and celebrate potential.
- We are Tenacious – We find a way, with energy, drive and enthusiasm.
- We Inspire – We nurture new possibilities, input, ideas and ways of working.

Achievements and performance

a. Review of activities

The new strategic plan for the charity was developed in 2022 throughout the rigorous process we reviewed the work of the charity to date. We widely consulted with a number of key stakeholders internally and externally to include people affected by Oesophageal Cancer and Barrett's Oesophagus, our partners, volunteers, family members, medical and research professionals and other peer support and advocacy organisations. Their advice and feedback guided our work in developing this plan and helped the Board and staff team in assessing current and future needs. This plan will guide the work and development of the charity until the end of 2026.

The Strategic Plan sets out four key ambitious strategic pillars we are committed to work in partnership with others to realise the goals of this plan.

The four strategic pillars of this plan are;

1. People affected by Oesophageal Cancer, their Families and Carers
2. Awareness, Prevention and Early Intervention
3. Leading Edge Research
4. Organisation Structure, Governance and Financial Sustainability

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements and performance (continued)

The Strategic Plan is also supported by four strategic drivers. These strategic drivers represent the key influencing factors that matter to the charity. Aligning with these strategic drivers in all we do will contribute to the success of The Oesophageal Cancer Fund achieving this Strategic Plan.

The Strategic Drivers for the Oesophageal Cancer Fund are;

- The experiences and needs of people affected by Oesophageal Cancer
- Working in partnership
- Empowering people affected by Oesophageal Cancer
- Innovation and improvement

The Four Strategic drivers will be used to test opportunities and operational activities for the Oesophageal Cancer Fund. When an opportunity is presented to the team and/or Board it is evaluated on whether it meets the strategic drivers.

Oesophageal Cancer Fund Public Statement on Compliance with the Charities Regulator Guidelines on Fundraising from the Public

The Oesophageal Cancer Fund is committed to adhering to the Charities Regulator guidelines for charitable organisations on fundraising from the public. The Oesophageal Cancer Fund does not receive statutory funding therefore, the charity is reliant on fundraising from the public. In accordance with the Charity Regulator guidelines for fundraising from the public, control of the organisation is independent of funding sources. The Oesophageal Cancer Fund is committed to carrying out all fundraising activities in an open, transparent, honest, respectful and accountable manner. The charitable activities undertaken in 2022 were enabled by the ongoing support of our donors and supporters.

b. Raising awareness of the symptoms of Oesophageal Cancer

The wider national community is also part of our focus. In 2022 we continued to raising awareness of the symptoms of Oesophageal Cancer. Early Diagnosis of Oesophageal Cancer, as with any type of cancer, is crucial. Early detection can vastly improve treatment options for those diagnosed and increase survival rates for Oesophageal Cancer. We worked in partnership with our Patron Padraig Harrington during Lollipop Day 2022 to make sure the general population is aware of the signs and symptoms of Oesophageal Cancer. These efforts were also generously supported by people affected by Oesophageal Cancer as well as OCF supporter Rachel Gorry who spoke in the media and shared their personal stories online to raise awareness. Lollipop Day was held in May 2022 and a key focus of this campaign was raising awareness of the symptoms of Oesophageal Cancer and we were supported in our efforts by our community volunteers.

c. Supporting people affected by Oesophageal Cancer

The Oesophageal Cancer Fund fosters a support community for people with Oesophageal Cancer, their families and carers to feel less alone and more connected. In 2022 we were unable to hold face to face support meetings however we continued to develop our information resources and launched a new website with further support resources for anyone requiring further information on Oesophageal Cancer and Barrett's Oesophagus. Where requests were made for peer information and support we matched survivors of Oesophageal Cancer with newly diagnosed patients.

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements and performance (continued)

d. Fundraising to provide funds for vital research

Through our fundraising efforts and the support received from our donors and supporters we continued our commitment to fund vital research into this disease. Oesophageal Cancer requires very specific and painstaking research. The Oesophageal Cancer Fund supports a variety of institutions that are on the very cutting edge of that research, helping to find innovative new treatments for patients in the areas of Early Diagnosis, Treatment and Survivorship. In 2022 we provided funding directly to carefully selected research projects specifically the Barrett's Oesophagus Registry and Biobank and the New Aegis Clinical Trial.

We have funded the National Barrett's Oesophagus Registry and Bio Bank since 2009, in 2020 Precision Oncology Ireland joined with OCF to jointly fund this programme we continued this partnership in 2022.

The Barrett's Oesophagus Registry, is a database that was established to meet our aim of combating Oesophageal Adenocarcinoma (OAC) through early detection. Employing registry personnel and linking five national hospitals: St. James Hospital, Beaumont Hospital, Mater Hospital, Mercy Hospital Cork and Galway University Hospital. To date 9,000 patients have been recorded on the Barrett's Registry. Though not cancerous, Barrett's Oesophagus is a condition that is frequently a precursor to Oesophageal Cancer. The Registry helps the medical professionals identify at-risk patients earlier and track their progress using endoscopies and biopsies. Cellular changes such as dysplasia and or cancer can be diagnosed much earlier, meaning Oesophageal Cancer can be addressed in its early and most treatable phase. In parallel with the registry, is the Barrett's Oesophagus National Bio Bank where tissue and blood samples are collected with patients' consent and used for research studies. This Bio Bank infrastructure supported by The Oesophageal Cancer Fund, has enabled students and researcher to apply to funding bodies to conduct further research using this collected material, to great success. Through this OCF-funded programme, collaborations have been formed with leading international groups in Barrett's Oesophagus and Oesophageal Cancer.

We continued to fund the Neo Aegis Clinical Trial in 2022 this is the final year of the trial. The Neo Aegis Clinical Trial is a major, international clinical trial led from Ireland by Clinical Trials Ireland that has recruited 377 people with Oesophageal Cancer, a third of whom [136 - 34%] are based in Ireland. The trial seeks to establish the best available treatment for patients presenting with advanced but potentially curable Oesophageal Cancer, and compares chemotherapy alone combined with surgery against a combination of chemotherapy and radiation therapy prior to surgery. The study has cemented two 'standard of care' treatment options for Oesophageal Cancer as 'equivalent', thereby keeping treatment options open and viable for patients with Oesophageal Cancer depending on regional and national networks. Importantly the outcomes have been excellent in both treatment arms. This result is particularly important bearing in mind the differing availability of treatment options in different regions nationally and internationally.

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review

a. Going concern

The financial statements have been prepared on the going concern basis. The Directors have reviewed the charity's obligations for the foreseeable future (a period not less than twelve months from the approval of these financial statements). The Directors are of the opinion that the charity has sufficient financial resources to meet its obligations as they fall due for the foreseeable future. On this basis, the Directors deem it appropriate to prepare the financial statements on the going concern basis.

b. Risk management objectives and policies

The Charity's risk management processes involve identifying risks across the Charity, assessing the potential impact of these risks and providing a method for addressing these potential impacts by either reducing threats to an acceptable level or taking steps to mitigate those risks.

The risk review process consists of activities to identify, categorise, describe, and assess risks. The outcome is a list of described risks which are clearly mapped to objectives and prioritised according to risk assessment criteria which are reviewed, challenged, discussed and agreed by the Directors. The described risks are reviewed annually and any additional risks that are recognised are incorporated into the register and given an appropriate risk score.

Structure, governance and management

a. Constitution

The Oesophageal Cancer Fund is registered as a charitable association with the Charities Regulator. As a registered charity, the Oesophageal Cancer Fund is subject to the Charities Acts and the guidelines issued by the Charities Regulator, such as the Charities Governance Code and the charity regulator guidelines for charitable organisations on fundraising from the public. The strategic direction and governance of the charity is the responsibility of the Board. The Board seeks people with suitable skills to serve on the Board and manages the process for the recruitment, appointment and rotation of Board members. Newly appointed Board members receive an induction programme covering responsibilities and involvement. The following were Board members of the charity, and unless indicated otherwise, served for the entire year:

David Ryan - Chairperson
Paul Paterson - Vice Chairperson
Sampada Lumba - Secretary
Martin Macdonnell
Marc Johnstone - Treasurer (joined March 2022)
Julie Colby (resigned April 2022)

The Board met seven times during the year for Board meetings outside of the strategic planning meetings.

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Structure, governance and management (continued)

Attendance at Board meetings is shown below:

	Attended
David Ryan - Chairperson	6/7
Paul Paterson - Vice Chairperson	7/7
Sampada Lumba - Secretary	4/7
Martin MacDonnell	7/7
Marc Johnstone - Treasurer (joined March 2022)	5/6
Julie Colby (resigned April 2022)	3/3

Throughout the year, the Board members did not receive any remuneration from the charity. In order to ensure that the charity is managed efficiently and effectively, the Board have delegated a range of day-to-day decision-making powers to the CEO. The Board have established appropriate controls and mechanisms to ensure that the staff team operate within the powers delegated by the Board.

b. Methods of appointment or election of Directors

The management of the Charity is the responsibility of the Directors who are elected and co-opted under the terms of the Trust deed.

Plans for future periods

As the voice for Oesophageal Cancer in Ireland for the past 21 years we have had a positive impact. After the initial period of activity, with a changing world, a cashless society, an evolving medical and cancer ecosystem for patient support, research and advocacy, the time is right to identify the why, what and when of our next 20 years.

The Charity is in the process of transitioning from a fund to a company limited by guarantee. This new body will bring the charity forward into a rapidly changing landscape with the impacts of the global pandemic and cost of living issues all factoring. We will view these challenges through the prism of our 2022-2026 Strategic Plan which will also identify areas of development in the key pillars we have identified. Our plan has been developed in conjunction with our key stakeholders, industry partners and our planning consultant, Caroline McCamley of & Ampersand.

This Strategic Plan will ensure that the Oesophageal Cancer Fund transitions into our next critical phase with a structure that reflects best practice corporate governance with a skilled and driven Board and an empowered and accountable management team. We are well positioned to take on external challenges and take advantage of opportunities for sustainable development and growth.

OESOPHAGEAL CANCER FUND

DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Statement of Directors' responsibilities

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable Irish law and Charities SORP Financial Reporting Standard 102.

Company law requires the Directors to prepare financial statements for each financial year. Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Directors at the time when this Directors' report is approved has confirmed that:

- so far as that Director is aware, there is no relevant audit information of which the charity's auditors are unaware, and
- that Director has taken all the steps that ought to have been taken as a Director in order to be aware of any relevant audit information and to establish that the charity's auditors are aware of that information.

Auditor

The auditor, Woods and Partners Limited Chartered Accountants and Registered Auditor, were appointed as auditor on February 2023 and have indicated their willingness to continue in office in accordance with the provisions of Section 383(2) of the Companies Act 2014.

Approved by order of the members of the board of Directors and signed on their behalf by:



David Ryan
(Chair of Trustees)

Date: 26 - 9 - 2023



Marc Johnstone
(Trustee)

OESOPHAGEAL CANCER FUND

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2022

	Note	Unrestricted funds 2022 €	Total funds 2022 €	Total funds 2021 €
Income from:				
Donations and legacies	3	9,653	9,653	434,199
Other trading activities	4	443,388	443,388	-
Other income	5	4,614	4,614	4,852
Total income		457,655	457,655	439,051
Expenditure on:				
Charitable activities	6	468,100	468,100	497,960
Total expenditure		468,100	468,100	497,960
Net movement in funds		(10,445)	(10,445)	(58,909)
Reconciliation of funds:				
Total funds brought forward		586,371	586,371	645,280
Net movement in funds		(10,445)	(10,445)	(58,909)
Total funds carried forward		575,926	575,926	586,371

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 13 to 22 form part of these financial statements.

**OESOPHAGEAL CANCER FUND
REGISTERED NUMBER: 701131**

**BALANCE SHEET
AS AT 31 DECEMBER 2022**

	Note	2022 €	2021 €
Current assets			
Debtors	11	6,840	4,871
Cash at bank and in hand		591,152	651,093
		597,992	655,964
Creditors: amounts falling due within one year	12	(22,066)	(69,593)
Net current assets		575,926	586,371
Total assets less current liabilities		575,926	586,371
Net assets excluding pension asset		575,926	586,371
Total net assets		575,926	586,371
Charity funds			
Restricted funds	13	-	-
Unrestricted funds	13	575,926	586,371
Total funds		575,926	586,371

The Charity's financial statements have been prepared in accordance with the Charities SORP Financial Reporting Standards 102; the Financial Reporting Standard applicable in the UK and Republic of Ireland ("FRS 102").

The financial statements were approved and authorised for issue by the Directors and signed on their behalf by:



David Ryan
(Chair of Trustees)
Date: 26-9-2023



Marc Johnstone
(Trustee)

The notes on pages 13 to 22 form part of these financial statements.

OESOPHAGEAL CANCER FUND

**STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2022**

	2022 €	2021 €
Cash flows from operating activities		
Net cash used in operating activities	(59,941)	(24,877)
Cash flows from investing activities		
Net cash provided by investing activities	-	-
Cash flows from financing activities		
Net cash provided by financing activities	-	-
Change in cash and cash equivalents in the year	(59,941)	(24,877)
Cash and cash equivalents at the beginning of the year	651,093	675,970
Cash and cash equivalents at the end of the year	591,152	651,093

The notes on pages 13 to 22 form part of these financial statements

OESOPHAGEAL CANCER FUND

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (second edition - October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2014.

Oesophageal Cancer Fund meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements have been presented in Euro (€) which is the functional currency of the Charity.

1.2 Going concern

The financial statements have been prepared on the going concern basis. The Directors have reviewed the charity's obligations for the foreseeable future (a period not less than twelve months from the approval of these financial statements). The Directors are of the opinion that the charity has sufficient financial resources to meet its obligations as they fall due for the foreseeable future. On this basis, the Directors deem it appropriate to prepare the financial statements on the going concern basis.

1.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income from charitable activities include income earned from the supply of services under contractual arrangements and from performance related grants which have conditions that specify the provision of particular services to be provided by the charity. Income from government and other co-funders is recognised when the charity is legally entitled to the income because it is fulfilling the conditions contained in the related funding agreements. Where a grant is received in advance, its recognition is deferred and included in creditors. Where entitlement occurs before income is received, it is accrued in debtors.

1.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

OESOPHAGEAL CANCER FUND

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1. Accounting policies (continued)

1.4 Expenditure (continued)

All expenditure is inclusive of irrecoverable VAT.

1.5 Government grants

Government grants relating to tangible fixed assets are treated as deferred income and released to the Statement of financial activities over the expected useful lives of the assets concerned. Other grants are credited to the Statement of financial activities as the related expenditure is incurred.

1.6 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.7 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.8 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

1.9 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Directors in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

2. Provisions available for audits of small entities

In common with many charities of our size, we use our auditors to assist with the preparation of the financial statements.

OESOPHAGEAL CANCER FUND

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

3. Income from donations

	Unrestricted funds 2022 €	Total funds 2022 €
Donations	9,653	9,653
	<u>9,653</u>	<u>9,653</u>
	<i>Unrestricted funds 2021 €</i>	<i>Total funds 2021 €</i>
Donations	434,199	434,199
	<u>434,199</u>	<u>434,199</u>

4. Income from other trading activities

Income from fundraising events

	Unrestricted funds 2022 €	Total funds 2022 €	<i>Total funds 2021 €</i>
5050 OCF	612	612	-
Christmas campaign	14,734	14,734	-
Corporates	15,958	15,958	-
Remember in September	25,957	25,957	-
Events general	177,464	177,464	-
In memory	4,090	4,090	-
Lollipop month	165,465	165,465	-
SM fundraising	7,391	7,391	-
Sporting events	31,717	31,717	-
	<u>443,388</u>	<u>443,388</u>	<u>-</u>

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

5. Other incoming resources

	Unrestricted funds 2022 €	Total funds 2022 €
Other income	<u>4,614</u>	<u>4,614</u>
	<i>Unrestricted funds 2021 €</i>	<i>Total funds 2021 €</i>
Other income	<u>4,852</u>	<u>4,852</u>

6. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2022 €	Total 2022 €
Expenditure on charitable activities	<u>468,100</u>	<u>468,100</u>
	<i>Unrestricted funds 2021 €</i>	<i>Total 2021 €</i>
Expenditure on charitable activities	<u>497,960</u>	<u>497,960</u>

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

7. Analysis of expenditure by activities

	Activities undertaken directly 2022 €	Total funds 2022 €
Expenditure on charitable activities	<u>468,100</u>	<u>468,100</u>

	<i>Activities undertaken directly 2021 €</i>	<i>Total funds 2021 €</i>
Expenditure on charitable activities	<u>497,960</u>	<u>497,960</u>

8. Auditors' remuneration

	2022 €	2021 €
Fees payable to the Charity's auditor for the audit of the Charity's annual accounts	<u>4,920</u>	<u>-</u>

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

9. Staff costs

	2022	2021
	€	€
Wages and salaries	180,780	158,223
Social security costs	19,951	17,235
	<u>200,731</u>	<u>175,458</u>

The average number of persons employed by the Charity during the year was as follows:

	2022	2021
	No.	No.
Administrative	<u>4</u>	<u>4</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded €60,000 was:

	2022	2021
	No.	No.
In the band €70,001 - €80,000	1	-

The total remuneration, comprising salary and employer pension contributions, paid in respect of key management personnel amounted to €77,000 (2021: €)

10. Directors' remuneration and expenses

During the year, no Directors received any remuneration or other benefits (2021 - €NIL).

During the year ended 31 December 2022, no Director expenses have been incurred (2021 - €NIL).

11. Debtors

	2022	2021
	€	€
Due within one year		
Trade debtors	6,263	2,034
Other debtors	577	2,837
	<u>6,840</u>	<u>4,871</u>

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

12. Creditors: Amounts falling due within one year

	2022	2021
	€	€
Trade creditors	5	351
Other taxation and social security	17,202	14,922
Other creditors	-	50,000
Accruals and deferred income	4,859	4,320
	<u>22,066</u>	<u>69,593</u>

13. Statement of funds

Statement of funds - current year

	Balance at 1 January 2022	Income	Expenditure	Balance at 31 December 2022
	€	€	€	€
Unrestricted funds				
General Funds - all funds	586,371	457,655	(468,100)	575,926
	<u>586,371</u>	<u>457,655</u>	<u>(468,100)</u>	<u>575,926</u>

Statement of funds - prior year

	Balance at 1 January 2021	Income	Expenditure	Balance at 31 December 2021
	€	€	€	€
Unrestricted funds				
General Funds - all funds	645,280	439,051	(497,960)	586,371
	<u>645,280</u>	<u>439,051</u>	<u>(497,960)</u>	<u>586,371</u>

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

14. Summary of funds**Summary of funds - current year**

	Balance at 1 January 2022 €	Income €	Expenditure €	Balance at 31 December 2022 €
General funds	586,371	457,655	(468,100)	575,926

Summary of funds - prior year

	<i>Balance at 1 January 2021 €</i>	<i>Income €</i>	<i>Expenditure €</i>	<i>Balance at 31 December 2021 €</i>
General funds	<i>645,280</i>	<i>439,051</i>	<i>(497,960)</i>	<i>586,371</i>

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2022 €	Total funds 2022 €
Current assets	597,992	597,992
Creditors due within one year	(22,066)	(22,066)
Total	575,926	575,926

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2021 €</i>	<i>Total funds 2021 €</i>
Current assets	655,964	655,964
Creditors due within one year	(69,593)	(69,593)
Total	586,371	586,371

16. Reconciliation of net movement in funds to net cash flow from operating activities

	2022 €	2021 €
Net expenditure for the year (as per Statement of Financial Activities)	(10,445)	(58,909)
Adjustments for:		
Increase in debtors	(1,969)	(3,067)
Increase/(decrease) in creditors	(47,527)	37,099
Net cash used in operating activities	(59,941)	(24,877)

OESOPHAGEAL CANCER FUND

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022**

17. Analysis of cash and cash equivalents

	2022	2021
	€	€
Cash in hand	591,152	651,093
Total cash and cash equivalents	591,152	651,093

18. Analysis of changes in net debt

	At 1 January 2022	Cash flows	At 31 December 2022
	€	€	€
Cash at bank and in hand	651,093	(59,941)	591,152
	651,093	(59,941)	591,152

19. Post balance sheet events

There were no events subsequent to the balance sheet date that requires disclosure or adjustment to the financial statements.

20. Approval of financial statements

The financial statements for the year ended 31 December 2022 were approved and authorised for issue by the Directors on September 2023.